Senator Josh Hawley of Missouri has introduced legislation aimed at revoking the Food and Drug Administration's approval of mifepristone, a medication that plays a central role in abortion procedures across the United States.

Mifepristone is part of a two-drug regimen used in medication abortions, which account for approximately two-thirds of all abortions performed in the country. The drug was first approved by the FDA in 2000 and is typically used in combination with misoprostol to terminate early pregnancies.

Hawley's proposed bill faces significant obstacles in Congress, where it would need approval from both the House and Senate before reaching the president's desk. The legislation represents part of ongoing efforts by some Republican lawmakers to restrict access to abortion medications following the Supreme Court's decision to overturn Roe v. Wade.

The FDA's approval process for medications involves extensive clinical trials and safety reviews. Mifepristone has been subject to various regulatory restrictions and court challenges in recent years, with ongoing legal battles over its accessibility and distribution requirements.

The introduction of this legislation comes amid a broader national debate over abortion access and medication availability, with different states implementing varying policies regarding reproductive healthcare services.